ライフサイエンスコーパス: clavulanate

1 when SHV-1 beta-lactamase is inactivated by clavulanate.

2 r-resistant S130G variant beta-lactamases by clavulanate.

3 illin-sulbactam, amoxicillin, or amoxicillin-clavulanate.

4 ch elude mechanism-based inhibitors, such as clavulanate.

5 ollowed by a 3-wk course of oral amoxicillin/clavulanate.

6 us mezlocillin, ticarcillin, and ticarcillin-clavulanate.

7 quent when testing ampicillin or amoxicillin-clavulanate.

8 etain the carbons of the oxazolidine ring of clavulanate.

9 compared with standard-dose amoxicillin plus clavulanate.

10 CI, 1.16-1.54]) was higher with amoxicillin-clavulanate.

11 ly treated with further cycle of amoxicillin/clavulanate.

12 in, ximelagatran, lapatinib, and amoxicillin-clavulanate.

13 noperative management (NOM) with amoxicillin/clavulanate.

14 only -Arg conferred resistance to ampicillin/clavulanate.

15 moniae , results in resistance to ampicillin/clavulanate.

16 mmon among children who received amoxicillin-clavulanate.

17 with a fixed concentration of 4 microg/ml of clavulanate.

18 8-fold increased resistance to the inhibitor clavulanate.

19 important difference compared to ampicillin/clavulanate.

20 amase inhibitors: sulbactam, tazobactam, and clavulanate.

21 c treatment to receive B-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) or placebo for 5

22 Amoxicillin 875 mg with clavulanate 125 mg plus either placebo (standard dose) o

23 t commonly implicated drugs were amoxicillin-clavulanate (21 of 96; 22%), diclofenac (6%), azathiopri

24 Among the children who received amoxicillin-clavulanate, 35% had initial resolution of symptoms by d

25 revealed universal resistance to amoxicillin-clavulanate (4:1), with 87.5% of isolates also resistant

26 ed in testing staphylococci with amoxicillin-clavulanate (5 of 127 isolates, 3.9%), pseudomonas with

27 enem infusion 3 times daily plus amoxicillin/clavulanate 500 mg/125 mg orally 3 times daily with 20 m

28 ients were randomized to receive amoxicillin/clavulanate 500/125 mg three times a day or placebo thre

29 icrog/ml versus 4 microg/ml; and ticarcillin-clavulanate, 512 microg/ml versus 16 microg/ml, respecti

30 Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) (n = 254) or placebo (n = 256)

31 t, we observed a 5-fold increase in K(i) for clavulanate (7.4 +/- 0.9 microM for Asn276Asp vs 1.4 +/-

32 A total of 117 patients with amoxicillin/clavulanate (74.1%) and 91 with placebo (59.9%) were con

33 as largely driven by amoxicillin/amoxicillin-clavulanate (75% of DAPs).

34 lities of amoxicillin (16 micrograms/ml) and clavulanate (8 micrograms/ml), alone and in combination

35 am [3.0/0.375 g q6 hours] +/- PO amoxicillin-clavulanate [800 mg/114 mg q12 hours]), each for 5 to 14

36 oli cultured with amoxicillin or amoxicillin/clavulanate, a beta-lactam and beta-lactamase inhibitor,

37 a-lactamases confer resistance to ampicillin/clavulanate, a beta-lactam/beta-lactamase inhibitor comb

38 he carbapenem class, such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evalu

39 ctivity is not dependent upon or enhanced by clavulanate, a beta-lactamase inhibitor.

40 duced liver injury (DILI) due to amoxicillin-clavulanate (AC) has been associated with HLA-A*02:01, H

41 ggests that both amoxicillin and amoxicillin-clavulanate, administered prophylactically over a period

42 nued efficacy of Augmenting (amoxicillin and clavulanate) after nearly 20 years of clinical use.

43 Amoxicillin-clavulanate (AMC) is among the most frequently prescribe

44 ng data on 3 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin).

45 s finally cleared when it was treated with a clavulanate-amoxicillin combination.

46 ted with isoniazid (nine), phenytoin (five), clavulanate/amoxicillin (15), and valproate (11).

47 patotoxicity caused by isoniazid, phenytoin, clavulanate/amoxicillin, or valproate occurring since 19

48 The MICs of amoxicillin with clavulanate, ampicillin, chloramphenicol, metronidazole,

49 cluding high-dose amoxicillin or amoxicillin-clavulanate and 3 injections of ceftriaxone; 3 had recur

50 of treatment failure between the amoxicillin-clavulanate and amoxicillin groups (relative risk [RR],

51 most notable exceptions include ticarcillin-clavulanate and ampicillin, both of which enrich for a l

52 range of beta-lactams (including amoxicillin-clavulanate and cefotaxime) were isolated from scouring

53 In contrast to beta-lactam-based inhibitors clavulanate and cefoxitin, compound 10 did not up-regula

54 beta-Lactam agents (amoxicillin-clavulanate and cefpodoxime-proxetil) are not as effecti

55 ciprofloxacin, chloramphinicol, amoxicillin-clavulanate and ceftriaxone.

56 The MICs of amoxicillin-clavulanate and ciprofloxacin for these strains clustere

57 f intrinsic resistance (>40%) to amoxicillin-clavulanate and first/second-generations of cephalospori

58 urinol and HLA-B*58:01, and both amoxicillin-clavulanate and nevirapine with multiple class I and II

59 is demonstrates that intravenous amoxicillin/clavulanate and oral amoxicillin might be the best proph

60 meanwhile, prescribing rates for amoxicillin-clavulanate and respiratory fluoroquinolones mostly decr

61 chemically inert species, with SHV-1, while clavulanate and sulbactam form a mixture of trans-enamin

62 tween participants randomized to amoxicillin-clavulanate and those randomized to placebo (17.3% in th

63 In contrast, amoxicillin clavulanate and troglitazone did not interfere with MDR3

64 resistance of M. tuberculosis to amoxicillin-clavulanate and vancomycin.

65 tam, aztreonam, ticarcillin, and ticarcillin-clavulanate and with P. aeruginosa versus mezlocillin, t

66 S130Gbeta-lactamases (+/- inactivation with clavulanate) and identified peptides modified at the act

67 istered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited marked in vitro

68 a-lactams (including penicillin, amoxicillin-clavulanate, and imipenem-cilastatin), and lipopeptides

69 c activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin.

70 and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generation cephalospo

71 only with ampicillin-sulbactam, ticarcillin-clavulanate, and/or clindamycin.

72 cefotaxime (91) alone or in combination with clavulanate; and the standard disk diffusion method with

73 s that meropenem, cefotaxime and ticarcillin-clavulanate are associated with significantly reduced sp

74 Meropenem and clavulanate are Food and Drug Administration-approved dr

75 Using clavulanate as an example, we also show that Raman cryst

76 Overall 35,252 patients received amoxicillin-clavulanate as outpatients, and DILI occurred in 1 of 23

77 gerus, an industrially important producer of clavulanate as well as cephem antibiotics, also produces

78 lues were 20%, 41%, and 67% with amoxicillin-clavulanate, as compared with 14%, 36%, and 53% with pla

79 Among amoxicillin- and clavulanate-associated cases of European ancestry, rs247

80 rongest association was with amoxicillin and clavulanate-associated DILI in persons of European ances

81 allographic structure of BlaC inhibited with clavulanate at a resolution of 1.7 A with an R-factor va

82 levofloxacin, ciprofloxacin, or amoxicillin-clavulanate at outpatient visits.

83 Either intravenous amoxicillin-clavulanate (at doses of 1 g and 200 mg, respectively) o

84 The results of amoxicillin-clavulanate (AUG) and ampicillin-sulbactam (A/S) suscept

85 nolone or comparator antibiotic (amoxicillin-clavulanate, azithromycin, cephalexin, clindamycin, and

86 The relatively short half-life of clavulanate can be adjusted by a procedure of "topping u

87 Previously it was shown that amoxicillin-clavulanate can provide clavulanate inhibition of ESBLs

88 ofloxacin), or oral beta-lactam (amoxicillin-clavulanate, cefadroxil, or cefpodoxime) antibiotics.

89 , benzylpenicillin, clindamycin, amoxicillin/clavulanate, cefazolin, ciprofloxacin, metronidazole, an

90 azobactam, ampicillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefotetan, ceftriaxone, cefoxit

91 al agents: amikacin, ampicillin, amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, erythromycin, i

92 strated high-level resistance to amoxicillin/clavulanate, cephalosporins, and aminoglycosides.

93 d-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides.

94 n combination with beta-lactamase inhibitor, clavulanate (Clav).

95 d the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for wome

96 d the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for wome

97 because of off-scale MICs that exceeded the clavulanate combination concentrations in the panel), th

98 The cefepime-clavulanate combination provided 88% sensitivity and 91%

99 evere alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone did not improve 2

100 ilure between those who received amoxicillin-clavulanate compared with amoxicillin, but amoxicillin-c

101 illin-tazobactam, meropenem, and ticarcillin-clavulanate conducted in 5 intensive care units across A

102 ollowed by oral ciprofloxacin or amoxicillin-clavulanate, depending on uropathogen susceptibility.

103 and R-free value of 0.212 for the m/ z +154 clavulanate-derived fragment observed in the active site

104 ing rifampicin to meropenem plus amoxicillin/clavulanate did not enhance short-term antibacterial act

105 confirmatory results were observed for both clavulanate disk augmentation (9/19) and BD Phoenix (5/1

106 um beta-lactamases (ESBLs) and with cefepime-clavulanate disk combinations.

107 k test (CLSI plus BA), and an aztreonam plus clavulanate disk test (ATM plus CA).

108 rd IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for the treatment

109 and increased susceptibility to amoxicillin-clavulanate during the chronic phase of infection.

110 Confirmatory clavulanate effects were seen for both inocula for all E

111 th acute otitis media to receive amoxicillin-clavulanate either for a standard duration of 10 days or

112 susceptibility were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pne

113 E. coli clinical isolates were subjected to clavulanate ESBL confirmatory testing employing disk aug

114 up," or adding one-half the concentration of clavulanate every second day, in order to allow accurate

115 namine and imine in the E166A variant, while clavulanate exists almost exclusively as trans-enamine i

116 al therapy with itraconazole and amoxicillin-clavulanate failed to resolve the infection.

117 Soaking of the crystals with ampicillin or clavulanate, followed by flash-freezing, has been carrie

118 ute otitis media, treatment with amoxicillin-clavulanate for 10 days tended to reduce the time to res

119 Children who were treated with amoxicillin-clavulanate for 5 days were more likely than those who w

120 r older who were prescribed amoxicillin plus clavulanate for acute bacterial sinusitis diagnosed in a

121 EM-84 (N276D), the water molecule activating clavulanate for cross-linking (Wat1614) is disordered (i

122 both amoxicillin and Augmentin (amoxicillin-clavulanate for use against beta-lactamase-expressing ba

123 acteriaceae (from 24% to 48% for amoxicillin-clavulanate, from 4% to 18% for cefotaxime, and from 5%

124 were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, -11.

125 tly lower in children in the amoxicillin and clavulanate group (9.04 [95% CI, 8.71 to 9.37]) compared

126 ated to liver failure (25 in the amoxicillin-clavulanate group and 20 in the placebo group), infectio

127 ointestinal disorders (15 in the amoxicillin-clavulanate group and 21 in the placebo group).

128 domized to placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [P = .3

129 bo group), infections (23 in the amoxicillin-clavulanate group and 46 in the placebo group), and gast

130 Clavulanate has potential to be used in combination with

131 Receipt of amoxicillin-clavulanate (HR, 6.48; 95% CI, 1.43-29.4; P = .02) and t

132 edium was 6.7 days, whereas the half-life of clavulanate in combination with amoxicillin was 2.0 days

133 (trihydrate and sodium) in combination with clavulanate in nonradiolabelled 7H12B medium was 6.7 day

134 ourse of antibiotic therapy with amoxicillin-clavulanate in patients receiving a 32-to-34 degrees C t

135 activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuberc

136 the half-lives of amoxicillin trihydrate and clavulanate in radiolabelled 7H12B medium were comparabl

137 ly) results in resistance to inactivation by clavulanate in the SHV-1 and TEM-1beta-lactamases.

138 ase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infec

139 ubstitutions at Arg-244 confer resistance to clavulanate inactivation.

140 Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly iden

141 Proteolytic digestions of purified forms of clavulanate inhibited TEM-2 beta-lactamase followed by a

142 electrospray ionization mass spectrometry of clavulanate-inhibited SHV-1 and SHV Asn276Asp showed nea

143 studies implied that no long-lived forms of clavulanate-inhibited TEM-2 beta-lactamase retain the ca

144 own that amoxicillin-clavulanate can provide clavulanate inhibition of ESBLs and protect an oral ceph

145 testing could detect favorable cephalosporin-clavulanate interactions among a group of 101 previously

146 ns of mild-to-moderate COPD with amoxicillin/clavulanate is more effective and significantly prolongs

147 rapy with oral ciprofloxacin and amoxicillin-clavulanate is safe and effective.

148 Co-amoxiclav (amoxicillin and clavulanate) is a commonly used combination antibiotic,

149 similar TEM enzyme, we observed increases in clavulanate k(inact) for all mutants.

150 ratory infections (azithromycin, amoxicillin-clavulanate, levofloxacin/moxifloxacin, cephalexin, and

151 combination of a beta-lactam antibiotic and clavulanate may lead to rapid bactericidal activity.

152 day, in order to allow accurate amoxicillin-clavulanate MIC testing with the BACTEC mycobacterial su

153 strated reduced susceptibility to ampicillin/clavulanate (MIC increased from 50/2 --> 50/8 microg/mL)

154 remained very active, including amoxicillin-clavulanate (MIC90s, < or =0.25 microg/ml), azithromycin

155 ) or avoid mechanism-based inhibitors (e.g., clavulanate), mutant serine beta-lactamases have not yet

156 ceive prednisolone combined with amoxicillin-clavulanate (n = 145) or prednisolone combined with plac

157 The implicated agents included amoxicillin/clavulanate (n = 3), temozolomide (n = 3), various herba

158 ired three twofold-dilution differences with clavulanate needed to confirm an ESBL primarily in the r

159 ounger than 19 for resistance to amoxicillin-clavulanate (odds ratio [OR], 1.43; 95% confidence inter

160 ed to receive either 40 mg/kg of amoxicillin-clavulanate or a placebo mixture per day for 7 days.

161 new prescription dispensation of amoxicillin-clavulanate or amoxicillin in a nationwide health care u

162 new prescription dispensation of amoxicillin-clavulanate or amoxicillin.

163 atients treated with fasiglifam, amoxicillin-clavulanate or flucloxacillin and in primary hepatocytes

164 e either oral ciprofloxacin plus amoxicillin-clavulanate or intravenous ceftazidime.

165 f stringent criteria, to receive amoxicillin-clavulanate or placebo for 10 days.

166 An oral fluoroquinolone plus amoxicillin/clavulanate (or plus clindamycin if penicillin allergic)

167 and lower odds of resistance to amoxicillin-clavulanate (OR, 0.56; 95% CI, .34-.96) (all P < .05).

168 nced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the

169 s combined with the beta-lactamase inhibitor clavulanate, potent activity against laboratory strains

170 dministration of 1,000/200 mg of amoxicillin/clavulanate provided the least incidence of postdental p

171 In contrast, clavulanate reacts with the enzyme quickly to form hydro

172 amases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity.

173 r-130 is the principal cause of the observed clavulanate resistance.

174 es tested that were resistant to amoxicillin-clavulanate (resistance breakpoint >/= 16/8 mug/ml), 7/7

175 ed for this study as quinolones, amoxicillin/clavulanate, second- and third-generation cephalosporins

176 HV-1 and S130Gbeta-lactamases inactivated by clavulanate showed that the formation of reaction interm

177 populations with ceftazidime and amoxicillin-clavulanate susceptibilities that differed among the cli

178 n eardrops (76 children) or oral amoxicillin-clavulanate suspension (77) or to undergo initial observ

179 among the children treated with amoxicillin-clavulanate than among those who received placebo: 4% ve

180 er for the children treated with amoxicillin-clavulanate than for those who received placebo (P=0.02)

181 A pilot study on amoxicillin-clavulanate that used a portion of the study animals dem

182 nt study on both amoxicillin and amoxicillin-clavulanate that used the remaining study animals, the a

183 y of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into

184 osis (Mtb) with the beta-lactamase inhibitor clavulanate together with meropenem resulted in rapid, p

185 Compared with amoxicillin-clavulanate treatment, the use of azithromycin and moxif

186 fied TEM-2 suggests rapid decarboxylation of clavulanate upon binding to the enzyme.

187 ceptible in vitro to ampicillin, amoxicillin/clavulanate, vancomycin, and teicoplanin.

188 ting intravenous amoxicillin and amoxicillin/clavulanate was administered.

189 risk of treatment failure after amoxicillin-clavulanate was an RR of 0.98 (95% CI, 0.86-1.12) for ag

190 ied risk of adverse events after amoxicillin-clavulanate was an RR of 1.23 (95% CI, 1.10-1.37) for ag

191 e compared with amoxicillin, but amoxicillin-clavulanate was associated with a higher risk of gastroi

192 ted only a bacteristatic effect; amoxicillin/clavulanate was inactive.

193 nsusceptibility to cefoxitin and amoxicillin-clavulanate was less specific than APBA testing; it iden

194 Recently, meropenem-clavulanate was shown to be effective against drug-resis

195 When clavulanate was tested alone, the half-life was determin

196 Amoxicillin-clavulanate was the most commonly implicated agent.

197 Amoxicillin/clavulanate was the most frequently prescribed (24.6%) a

198 A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of

199 The MICs of amoxicillin-clavulanate were higher than that of ampicillin alone, a

200 line and amoxicillin (alone or combined with clavulanate) were the medicines affected in the highest

201 imal inhibitory concentrations to ampicillin/clavulanate when expressed in Escherichia coli.

202 detect and predict resistance to amoxicillin/clavulanate which is driven by over-expression of this g

203 All participants received amoxicillin/clavulanate with each meropenem dose.

204 A mechanistic scheme for the reaction of clavulanate with TEM-2 beta-lactamase is proposed in whi

205 ified proteins are formed upon incubation of clavulanate with the TEM-2 enzyme.